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Abstract
Papillary thyroid carcinoma is a slow-growing cancer with a generally good prognosis that sometimes have an
aggressive behaviour. Metastases to neck lymph nodes is the first step of the diffusion. The central neck compartment is
involved most commonly. The ipsilateral lateral neck compartments are usually involved afterwards, and the involvement
of the contralateral one is considered a quite rare occurrence. In more rare cases, metastases to lateral neck compartment
without central lymph node metastasis (so called “skip metastases”) could be observed. Aim of this literature review study
is to analyse the average incidence, pattern and risk factors of this occurrence.
This study was performed according to PRISMA criteria. A final selection of 13 articles published in English language from
1997 to 2017 was performed. Any research article, review or meta-analysis was taken into consideration. Research was
expanded considering the related references of articles.
The incidence of skip metastases ranged from 1.6 to 21.8%. Risk factors such as age > 45 years, size < 5mm and tumor
located in the upper pole or isthmus of thyroid gland were found.
Due to the frequency of skip metastases in thyroid cancer, a careful preoperative examination of lateral lymph nodes
should be necessary.
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Introduction
Papillary thyroid carcinoma (PTC) is slow-growing can-
cer and has generally a good prognosis for the majority
of patients with a 5 years survival of 97–99% according
to literature data [1–3].
Despite this excellent prognosis, some PTC and some-
times papillary thyroid microcarcinoma (PTMC), have
an aggressive medical behaviour with an increase in
mortality in some patients, as a consequence of molecu-
lar biology changes and other unclear causes [4–7].
Regional lymph node metastases are commonly ob-
served in PTC and the risk of local regional recurrence
occurs in 30–80% of cases [4, 8]. The central neck re-
gion is involved most commonly, increasing the overall
morbidity and mortality as a potential consequence of
increased risk of local recurrence [2, 5–7, 9, 10]. In
spite of these observations, guidelines available up till
now (2015 ATA guidelines) are cautious in extending
indications for prophylactic central neck dissection
(recommendation 36) and, on the other hand, restrict
indication for lateral neck dissection only in the pres-
ence of biopsy-proven metastatic lateral compartment
involvement (recommendation 37) [11].
According to the majority of papers available in litera-
ture, routine prophylactic node dissection is not indi-
cated for all patients with PTC, in particular in small
size tumors (T1 and T2) so pathological lymph nodes
should be systematically identified preoperatively to
avoid reoperation associated with a higher complication
rate [2, 3].
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The first anatomical site involved is the central com-
partment followed by the ipsilateral lateral compartment.
Controlateral lateral compartment seems to be rarely in-
volved [7, 12, 13].
The surgical treatment depends on the characteristics
and evolution of PTC [5].
The risk factors of cervical metastases would appear to
be the following: young age (< 45 years), multifocality,
tumor size (> 0,5 cm) and site [6].
Zhang et al. [14] showed that the rate of lateral neck
in the PTMC are located more frequently in upper pole
than in middle portion of thyroid gland; in their experi-
ence PTMC located in upper pole of thyroid gland was
associated with a reduced incidence of central lymph
nodes metastases.
Xiang et al. [6] find 57.5% of central metastases in the
PTMC located in the middle third of the thyroid gland.
Other authors emphasize a correlation with PTC lo-
cated in the upper pole and development of lateral neck
metastases [6, 7, 14, 15].
However, controversies remain regarding the correlation
between tumor location and neck metastasis in PTMC [6].
Total Thyroidectomy with central neck dissection
(CND) is recommended for patients with PTC according
current guidelines but [6, 16] controversies still exists
about the extension of cervical lymphadenectomy [6].
Despite the behaviour, some patients develop lateral
lymph node metastasis without central lymph node me-
tastasis. A lateral metastasis in the absence of a central
one is defined skip metastasis.
According to literature, skip metastases occur with the
dissemination of PTC cells through the lymphatic sys-
tem gradually [5, 13].
Its incidence is variable according different studies.
In Jianyong Lei et al. experience, the incidence of skip
metastases ranged from 6.8–37.5%.
According to other authors, this incidence varies be-
tween 11.1 and 37.5% [13].
In literature, many articles describe cases of skip metas-
tasis but their behaviour unpredictable and small patients
sample reported make their characterization difficult.
The present study revised the literature concerning
skip metastases, with the aim of analysing average inci-
dence, their pattern and risk factors.
Materials and methods
This study was performed according to PRISMA criteria
[17]. According to these guidelines, the selection of pa-
pers included has been carried out as follows.
Literature search strategy
A systematic and comprehensive review of full texts was
realized with literature research on PubMed. It included
articles published in English language from 1997 to
2017. Medical Subject Heading (MESH) used for inter-
net research were: “thyroid skip metastases”, “recurrence
thyroid cancer”, “papillary thyroid carcinoma metasta-
ses”, “lymphadenectomy” with the Boolean operators
AND or OR. In a first step of recruitment, all titles and
abstracts of the identified studies for inclusion were eval-
uated. In a second phase a screening of full-text con-
cerned the qualitative assessment of studies.
Selection criteria
Clinical trials, systematic review and meta-analysis arti-
cles were included. Case reports were considered only in
the presence of substantial theoretical knowledge. Accord-
ing to a collective decision of all Authors of this manu-
script, we included in the systematic review all articles
that reported incidence and described behaviour and risk
factors of skip metastases. Our research was expanded
considering the related references of articles. Articles
concerning poorly differentiated or undifferentiated car-
cinomas were excluded. Articles concerning pediatric pa-
tients, concomitant diseases such as hyperparathyroidism,
tumours arising from organs different from thyroid gland
were also excluded.
Study selection
At first, a total of 49 articles were considered in compli-
ance with search strategy. The search process, that led
to the final 13 selected articles was carried out as in
Fig. 1.
Literature analysis
Incidence
The incidence of skip metastases varies in a wide range.
Some studies analyse only its occurrence: Lee et al. [9]
between 55 PTC analysed found 3 skip metastases; there
are no other data on these 3 cases; Roh et al. [4] ana-
lysed 22 patients who underwent surgery for lateral
nodal recurrence of PTC and found three skip metasta-
ses (14%). In another study the same Author [2], among
52 patients that underwent in all cases total thyroidec-
tomy, CND and lateral neck dissection, found five skip
metastases. (9.6%). According to Lei et al. [6], its inci-
dence is 8.7%.
Xiang et al. [6] reports 11 skip metastases in 949
PTMC included (1.6%). A recent article of Lei et al. [7]
reported an incidence of 39 skip metastases in 450 pa-
tients analysed (8.7%). To the best of our knowledge, it
is the biggest case studies of skip metastases in litera-
ture. Zhan et al. [18] found 29 skip metastases among
272 patients enrolled (10.6%). Nie et al. [5] in their series
of 261 patients with PTC found 30 (14.8%) skip metasta-
ses. Park et al. [15] found 32 skip metastases in 147 pa-
tients (21.8%). Chung et al. [18] included 245 patients
with PTC. Among these patients, in 39 undergoing CND
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plus lateral neck dissection (LND), the authors found 12
with lateral metastases and 3 skip metastases (7.7%).
The biggest series published in the literature are re-
ported in the following three articles that we want to
highlight: Wada et al. [19] in 231 patients included, all
treated with total thyropoidectomy (TT), CND and ipsi-
lateral lateral dissection, found 17 skip metastases; Xiao
et al. [20] enrolled 121 patients that underwent TT with
CND and LND and they found nine skip metastases. In
this study, a rate of incidence of 14.1% (9/64 lateral me-
tastases) was reported.
Concerning the incidence, there is a wide variability
from study to study.
Park et al. [15] report an average of 21.8% and finally
Nie et al. [5] find an incidence of skip metastases of
14.8%.
In summary, in all studies consulted the incidence of
skip metastases ranges from 1.6 to 21.8% (Table 1).
Fig. 1 Screening of search results
Table 1 Studies published
Authors Years N°
Patients
Type of Surgery TT+ Skip metastases Tumor site Tumor size Capsular
invasionCND CND + LND N° Upper pole Middle portion < 10 > 10
Ducci M 1997 36 36 50 ispilateral
14controlateral
11.1% NE NE NE NE NE
Machens A 2004 215 215 95.3%ipsilateral
73.5% controlateral
13 (19.7%) NS NS NS NS NS
Roh JL 2007 22 22 NS 3 (13,7%) NE NE NE NE NE
Roh JL 2008 52 52 57 5 NS NS NS NS NS
Wada N 2008 231 231 231 ipsilateral 17 NS NS NS NS NS
Chung IS 2009 245 245 39 (12 metastases) 3
Xiao GZ 2010 121 121 121 9 NS NS NS NS NS
Park JH 2012 147 147 147 32 (21.8%) NS NS 32 NS NS
Xiang D 2015 949 949 44 11 8 3 NS NS NS
Lei J 2017 450 450 450 39 (8.7%) 37 (94.9%) 2 (5.1%) 71.8% NS 84.6%
Zhan X 2017 272 TT NS 29 (10.7%) 95% NS 95% NS NS
Xlin N 2017 203 203 203 30 (14.8%) 19
Lee B 2017 55 NS 55 3 NS NS NS NS NS
TT Total Thyroidectomy, CND central neck dissection, LND Lateral lymphoadenectomy, NE non evaluated, NS non specified
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Risk factors
From the analysis of literature, it would seem that site,
size and capsular invasion of primary cancer could affect
development of skip metastases. In support of this hy-
pothesis, the article of Lei (6) showed that primitive
PTC commonly had capsular invasion (84.6% vs 52.8%,
P > 0.001), it was PTMC (71.8% vs 16.3%, P > 0.001), as
confirmed in other articles [19] and most frequently was
located in the upper thyroid portion except in two cases
that were located in the middle portion. When all three
risk factors (primary tumor located in the upper thyroid
portion, tumor size < 10mm and capsular invasion) were
associated, the authors demonstrate the predictability of
skip metastasis with the specificity of 0.98 and the Area
Under Curve (AUC) was 0.7.
The importance of site of primary cancer is also em-
phasized by Xiang [6]. In this study, CND was realized
for all patients. For bilateral and multifocal tumors or
cancer located in the isthmus, ipsilateral CND was per-
formed (236 patients). Central neck metastases were
found in 299 patients (31.5%) and lateral neck metasta-
ses in 44 (4.6%). These 44 patients had lymphadenec-
tomy from II to IV level. The skip metastases occurs
only in tumors located in the upper poles (8 patients)
and in middle portion of thyroid gland (3 patients).
These results confirm that the tumor site is an import-
ant risk factor in the development of skip metastases. In
this analysis, owing to small number of skip metastases
found, no statistical conclusions were made. Chung [18]
did not find any risk factor associated to skip metastases,
probably because of the small number of cases of CND
or LND (n = 3) and CND + LND (n = 9).
Zhan and coll [21] also underline the importance of
association between tumor size (< 10mm), tumor site
(upper pole of thyroid gland) and age of patients (> 45
years old) to develop skip metastases.In their experience,
95% of patients with skip metastases had a PTC located
in the upper pole.
In the article of Nie [5] the inverse relation between
tumor size and incidence of skip metastases was empha-
sized: in fact, the Author found it more frequently in
PTMC especially when tumor size was ≤ 5 mm.
Park and coll. [15] report that skip metastases were
less common (12.5% vs 30.4%) with multifocal tumors.
Moreover, there were no differences in terms of age, sex,
tumor bilaterality, tumor extension in the group with
and without skip metastases. On the contrary, a signifi-
cant association between skip metastases, primary tumor
location and size was showed. Tis could be explained by
the possible correlation between skip metastases and
tumor located in the upper pole for possibly migration
via lymphatic drainage accompanying the superior thy-
roid artery. In this study the primary tumor was < 1 cm,
and presented single focus.
As regards as histology of primary tumor, from 215
patients included by Machens et al. [13] 66 were papil-
lary, 8 follicular and 141 were medullary thyroid cancer.
The Authors found 13 skip metastases (19.7%) in 66
papillary thyroid cancers and 30 (21.3%) in 141 medul-
lary thyroid cancer.
Finally, capsular invasion and age > 45 years are pos-
sible risk factors underlined in some studies [18, 21].
Pattern and localization of metastases
Skip metastases showed most frequently Level II metas-
tases and less usually Level III, IV and V metastases. The
PTC skip metastases showed a very high number of
single-level metastases in the lateral compartment more
rarely triple-and quadruple-level metastases [6, 7].
According to Park [15] the group with skip metastases
had an inferior number of metastases of lateral nodes
(3.3 ± 2.5 vs. 5.8 ± 3.5; p < 0,001) probably because these
were found more frequently at a single level (53.1% vs.
20%; p < 0.001). In the group with skip metastases, these
were found more frequently at levels III or II, a single
cervical level and only a single node were involved. In
support of the pathophysiologic hypothesis concerning
the role of lymphatic drainage running close the superior
thyroid artery, the levels III and II were most frequently
involved in patients with skip metastases, so primary
tumor located in upper pole tends to metastasize to
upper levels rather than to the others levels.
Discussion
The causes leading a metastasis to skip the central com-
partment are not completely clarified yet. At present,
only risks factors could be invoked and few pathogenetic
mechanism would be assumed.
Zhang et al. [14] underlined the importance of age
> 45 years (95%), presence of microcarcinoma (95%),
tumor site (cancers located in the upper pole of the
thyroid gland showed incidence of 95%).
To predict a possible existence of skip metastases and
to know their natural history could help the surgeon in
establishing surgical strategy, performing total thyroidec-
tomy with adequate lymphectomy especially avoiding
reoperations for recurrence, with an increase in morbid-
ity and a worsening in prognosis.
Tumor locations, age, sex and tumor size can be con-
sidered strong risk factors and they can be useful in pre-
operative stratification of patients.
In the most of articles concerning skip metastases, the
first tumor is PTMC.
In a recent analysis is proven that tumor size > 0.5 is cor-
related with both central and lateral metastases. In this ana-
lysis tumor size > 0.5 cm is an important risk factor [7].
Other authors [5] underline the correlation with tumor
size less than 0.5 cm in diameter and skip metastases. In
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this analysis the authors show that the primary tumor lo-
cation in the context of the upper pole of thyroid gland
was significantly associated with lateral lymph node me-
tastases (p = 0.000, OR = 10.471, 95%). In detail, in this
analysis, a tumor located in the upper pole was more
aggressive and it was correlated to development of skip
metastases. This correlation can be explained by the
lymphatic drainage system. Thyroid gland has rich lymph-
atic drainage [9]. Most usually affected lymph node levels
in differentiated thyroid carcinoma are those of the anter-
ior compartment group (VI) and the internal jugular chain
(II-III-IV); less often those of the posterior triangle group
(V); submental (Ia) and submandibular (Ib) nodes are only
exceptionally involved (Fig. 1). An impressive work on ca-
daveric dissection was performed and previously pub-
lished in Japanese literature by Sato et al. in 1994 [22] and
subsequently published in English for the first time by
Likhterov et al. in 2017 [23]. In this publication, the
lymphatic system draining the thyroid gland was closely
evaluated to explain the patterns of metastatic spread in
patients with PTC. The anatomy of lymphatic channels
coming from the gland explains the different ways of DTC
metastasization to cervical lymph nodes. Although the
central compartment lymph nodes seem to be the first
step of lymphatic drainage before tumour cell transit to
the lateral compartment, lymphatic drainage through su-
perior lymphatic channels is directed from the central
neck directly to levels II and III of the lateral neck; this ex-
plains the possibility of skip methastases occurrence.
Some authors [24–26] have reported that the lobes of
thyroid gland have its own internal lymphatic system and
no communication with controlateral regional lymph
nodes. Although it is generally accepted that lymphatic
drainage occurs from the thyroid primarily to the central
lymphatic compartment and secondarily to the lateral
compartment nodes, there are not many data about skip
metastases and they are unpredictable.
Cervical metastasis occurs approximately in 35–80%
of cases of PTC. They increase the risk of locoregional
tumor recurrence and reoperation [9].
We would underline that most of selected studies have
some limitations ad biases: as showed in Table 1, most
papers did not report data about tumor size, site and
capsular invasion.
As regards as treatment guidelines, complication
commonly experienced from surgeons [27–35] that
are more frequent after more extended neck proce-
dures compared to standard thyroidectomy could in-
fluence in its turn the choice of performing a neck
dissection in the absence of proven localization at
central or lateral lymph nodes. Finally, it should be
taken into consideration that in high-risk patients lat-
eral lymph node involvement seems to be more fre-
quent [36–38].
Conclusion
In summary, according to this literature review, we can
define “the high risk patient” by the following features:
papillary or medullary PTMC located in upper pole or
isthmus, unifocal. Due to frequency of skip metastases,
that are rarely but not unusually found, a meticulous
preoperative examination of all lateral lymph node com-
partments, especially in a typical “high risk patient”,
should be necessary. In these patients the lymph nodes
suspected for metastatic involvement should be identi-
fied at ultrasound exam, a biopsy should be also per-
formed Moreover, a dosage of thyroglobulin in the
eluate could confirm the diagnosis. Owing to the typical
involvement of a single level a selective lateral neck dis-
section of the involved compartment seems to be an ac-
ceptable choice in most cases. The role of systematic
lymphadenectomy is controversial considering the low
aggressiveness of the PTC. However, it is necessary to
distinguish patients at high risk to develop recurrences.
Total Thyroidectomy with extended lymphadenectomy
may be indicated in high-risk patients, in whom lymph
nodal recurrence is more frequent.
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